Hepatitis B: Diagnosis and treatment

American Family Physician

Volumn 81, Issue 8, 2010, Pages 965-972

  Wilkins, Thad ^a   Zimmerman, Dave ^a   Schade, Robert R ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HEPATITIS B VACCINE; ENTECAVIR; HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; HEPATITIS A HEPATITIS B VACCINE; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B VACCINE; LAMIVUDINE; LIVER ENZYME; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PEGINTERFERON ALPHA2A; RECOMBINANT HEPATITIS B VACCINE; TELBIVUDINE; TENOFOVIR DISOPROXIL; VIRUS DNA; ALPHA INTERFERON; ANTIVIRUS AGENT; HEPATITIS B ANTIBODY; HEPATITIS B ANTIGEN;

ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; DISEASE ACTIVITY; DRUG INDICATION; GENETIC VARIABILITY; HEPATITIS B; HEPATITIS B VIRUS; HEPATOMEGALY; HUMAN; IMMUNOLOGICAL TOLERANCE; JAUNDICE; LIVER BIOPSY; LIVER CELL CARCINOMA; PREGNANCY; PREVALENCE; RISK FACTOR; SEROCONVERSION; SPLENOMEGALY; URINALYSIS; VACCINATION; VIRUS REPLICATION; BLOOD; CHRONIC DISEASE; PRACTICE GUIDELINE;

ANTIVIRAL AGENTS; CHRONIC DISEASE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B ANTIGENS; HEPATITIS B VACCINES; HUMANS; INTERFERON-ALPHA; PRACTICE GUIDELINES AS TOPIC;

EID: 79953663171     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Dienstag JL. Hepatitis B virus infection. N Engl J Med. 2008,359(14): 1486-1500.
2. Hui CK, Leung N, Yuen ST, et al., for the Hong Kong Liver Fibrosis Study Group. Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase. Hepatology. 2007;46(2):395-401.
3. Weinbaum CM, Williams I, Mast EE, et al., for the Centers for Disease Control and Prevention (CDC). Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep. 2008;57(RR-8):1-20.
4. Kim WR. Epidemiology of hepatitis B in the United States. Hepatology. 2009;49(5 suppl):S28-S34.
5. Schaefer S. Hepatitis B virus taxonomy and hepatitis B virus genotypes. World J Gastroenterol. 2007;13(1):14-21. (Pubitemid 46165459)
6. Lok AS, McMahon BJ. Chronic hepatitis B [published correction appears in Hepatology 2007;45(6):1347], Hepatology. 2007;45(2):507-539.
7. Baumert TF, Thimme R, von Weizsäcker F. Pathogenesis of hepatitis B virus infection. World J Gastroenterol. 2007;13(1):82-90.
8. Sorrell MF, Belongia EA, Costa J, et al. National Institutes of Health consensus development conference statement: management of hepatitis B. Hepatology. 2009,49(5 suppl):S4-S12.
9. U.S. Food and Drug Administration. Comvax (Haemophilus b conjugate vaccine [meningococcal protein conjugate]) and hepatitis B vaccine (recombinant). http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ ApprovedProducts/ucm174757htm. Accessed December 3, 2009.
10. Centers for Disease Control and Prevention. Pediatrix vaccine: questions and answers. http://www.cdc.gov/vaccines/vpd-vac/combo-vaccines/pediarix/faqs- hcp-pediarix.htm. Accessed December 3, 2009.
11. Mast EE, Margolis HS, Fiore AE, et al., for the Advisory Committee on Immunization Practices (ACIP). A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents [published corrections appear in MMWR Morb Mortal Wkly Rep. 2006;55(6):158-159, and MMWR Morb Mortal Wkly Rep. 2007;56(48):1267]. MMWR Recomm Rep. 2005;54(RR-16):1-31.
12. Chen W, Gluud C. Vaccines for preventing hepatitis B in health-care workers. Cochrane Database Syst Rev. 2005;(4):CD000100.
13. Fontana RJ, Lok AS. Hepatitis B. American College of Physicians Physicians' Information and Education Resource (PIER), 2009. http://pier.acponline.org/physicians/diseases/d476/d476.html [subscription required). Accessed October 12, 2009.
14. Mast EE, Weinbaum CM, Fiore AE, et al., for the Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part II: immunization of adults [published correction appears in MMWR Morb Mortal Wkly Rep. 2007;56(42):1114]. MMWR Recomm Rep. 2006;55(RR-16):1-33.
15. Lee C, Gong Y, Brok J, Boxall EH, Gluud C. Hepatitis B immunisation for newborn infants of hepatitis B surface antigen-positive mothers. Cochrane Databse Syst Rev. 2006;(2):CD004790.
16. Petrosillo N, Ippolito G, Solforosi L, Varaldo PE, Clementi M, Manzin A. Molecular epidemiology of an outbreak of fulminant hepatitis B. J Clin Microbiol. 2000;38(8):2975-2981. (Pubitemid 30642558)
17. Delaney WE IV, Borroto-Esoda K. Therapy of chronic hepatitis B: trends and developments. Curr Opin Pharmacol. 2008;8(5):532-540.
18. Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol. 2008;6(12):1315-1341.
19. Shamliyan TA, MacDonald R, Shaukat A, et al. Antiviral therapy for adults with chronic hepatitis B: a systematic review for a National Institutes of Health Consensus Development Conference. Ann Intern Med. 2009; 150(2):111-124.
20. Lai CL, Yuen MF. The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points. Ann Intern Med. 2007;147(1):58-61.
21. Lau GK, Piratvisuth T, Luo KX, et al., for the Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005;352(26):2682-2695. (Pubitemid 41007823)
22. Singh NA, Reau N. Management of hepatitis B virus. J Antimicrob Chemother. 2008;62(2):224-228. (Pubitemid 351984764)
23. Andreani T, Serfaty L, Mohand D, et al. Chronic hepatitis B virus carriers in the immunotolerant phase of infection: histologic findings and outcome. Clin Gastroenterol Hepatol. 2007;5(5):636-641. (Pubitemid 46660766)
24. Hadziyannis SJ, Papatheodoridis GV. Treatment of HBeAg negative chronic hepatitis B with new drugs (adefovir and others). J Hepatol. 2003; 39(suppl 1):S172-S176. (Pubitemid 37222668)
25. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al., for the Adefovir Dipivoxil 438 Study Group. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B [published correction appears in N Engl J Med. 2003;348(12):848-850]. N Engl J Med. 2003;348(9):800-807.
26. El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 2008;134(6): 1752-1763. (Pubitemid 351615415)
27. Wun YT, Dickinson JA. Alpha-fetoprotein and/or liver ultrasonography for liver cancer screening in patients with chronic hepatitis B. Cochrane Database Syst Rev 2003;(2):CD002799.
28. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130(7): 417-422.
29. Singal A, Volk ML, Waljee A, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009;30(1):37-47.
30. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340(10):745-750. (Pubitemid 29114292)